Ranbaxy Denies Being Barred From Germany
Advertisement
Advertisement
In a clarification to the National Stock Exchange (“The development pertains to only the Company’s cephalosporin injectable unit at Dewas in Madhya Pradesh. The European authorities along with those from Australia and Canada carried out an inspection in June 2014 of all the facilities in Dewas. Well before that time, the Company had decided, to stop producing cephalosporin injectables at Dewas,” said the company in its letter.
In a regular correspondence with the company, the exchange had sought a clarification from the company after a media report stated that Germany had banned certain drugs (anti-biotic) produced in the Dewas facility. The report suggested that the authorities in Germany had also communicated the same to
However, the company begs to differ. “…Since then, the agencies have approved all our facilities for manufacturing Dosage Forms and APIs (Active Pharmaceutical Ingredients) at Dewas including that for oral cephalosporins with the only exception of the cephalosporin injectable unit. We wish to state that Ranbaxy's decision to discontinue manufacture of Cephalosporin injectables would not have a significant impact on the business,” stated the company.
Ranbaxy also asserted that it has all the necessary approvals to produce drugs, which cover other manufacturing units of the company.
Advertisement
Representational Image: Indiatimes.com
Advertisement
- I'm an interior designer. Here are 10 things in your living room you should get rid of.
- A software engineer shares the résumé he's used since college that got him a $500,000 job at Meta — plus offers at TikTok and LinkedIn
- Higher-paid employees looking for work are having a tough time, and it could be a sign of a shift in the workplace
- AMD set to fuel growing demand for AI compute, says CTO
- Sensex tumbles 700 points amid broad-based selloff; Nifty slips from record
- Global smartphone shipments grow by 6% in Q1 2024, Samsung retakes the top spot
- Adani Green Energy Q4 net profit declines 39 pc to Rs 310 cr due to rising expenses
- Rupee rises 3 paise to end at 83.43 against US dollar
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market